about
Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approachProposals for model-based paediatric medicinal development within the current European Union regulatory frameworkContribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review.Current issues in oncology drug development, with a focus on Phase II trialsBiomedical informatics and outcomes research: enabling knowledge-driven health care.Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab.Biomarkers in drug discovery and development: from target identification through drug marketing.A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.Clinical trial simulation: a tool for understanding study failures and preventing them.Generating Virtual Patients by Multivariate and Discrete Re-Sampling TechniquesStatistical methods for HIV dynamic studies in AIDS clinical trials.Cost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review.Assessing the interruption of the transmission of human helminths with mass drug administration alone: optimizing the design of cluster randomized trials.Population pharmacokinetic studies in pediatrics: issues in design and analysis.Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.Designing More Efficient Preclinical Experiments: A Simulation Study in Chemotherapy-Induced Myelosupression.Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and DocumentationAre population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavirClinical trial simulation: a review.Importance of protocols for simulation studies in clinical drug development.An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.Probabilistic risk analysis: improving early drug development decision making.Role of modeling and simulation in pediatric investigation plans.Role of modelling and simulation: a European regulatory perspective.Physiologically based pharmacokinetic (PBPK) modeling in children.The current role of model-based drug development.Model-based clinical drug development in the past, present and future: a commentary.Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)Optimizing drug development in oncology by clinical trial simulation: Why and how?Multiscale Modeling in the Clinic: Drug Design and DevelopmentPharmacology-based toxicity assessment: towards quantitative risk prediction in humans.Whither pharmacometrics?: present state and future choices.Demonstrating bioequivalence using clinical endpoint studies.Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.Betting on the fastest horse: Using computer simulation to design a combination HIV intervention for future projects in Maharashtra, India.Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist.
P2860
Q24652176-4A45F68B-2939-4FEE-9E5C-7B2F2A7487B6Q28749999-A08E520B-0CA1-481F-B02E-DF0DCA9EE8EDQ33373185-27BA4CAA-278A-4025-A3C9-458F3391BBE0Q33433456-8C0B27C5-F74B-4C68-B137-A5CFEE43B262Q33624083-D96B7A4C-54EB-4F09-A012-4DC423797AB8Q33997068-27A57596-A490-44A6-8B2C-2068FA5C88C4Q34918726-86A0AE05-E905-4082-8807-8DEA700C9C7FQ35118033-CD105E8E-429C-4FB4-974F-78625F9CFBE4Q35826528-761964AC-8F1C-4BC4-9CBC-7B8F778C5985Q35827649-B9E5EA99-2281-4A59-97F9-6D39078BEB1EQ36055589-E19878AB-A15C-4477-8ABB-49F12C6F28E2Q36080108-75CD90E6-06FD-4938-AF08-2CA563B0BB20Q36088015-4885EB8E-FB86-4B42-B245-BEC9A3454244Q36276324-651EB9D6-98ED-44AA-9B90-90284450C6FEQ36284500-35454430-B0C1-4B44-AE15-48452006AF08Q36341632-22D84ABD-90C2-42E2-8AC3-72F17DDF3680Q36341664-C8C6B275-FF29-45EE-B299-86381AA452A0Q36618085-5627B0B3-CCE5-4737-8AB2-5F3342BA0929Q36734132-17623EC0-EA07-4B16-BAAA-A47DD74CEBBAQ36747438-0ED54327-3148-45EB-A02A-E585321F93BDQ36777485-17ABF7F1-02F4-422A-9D11-C3824E46921FQ37032799-A6BE6DCB-CA45-4D21-9E05-43723E6D4DDBQ37770955-596FF7E9-4B88-498E-995C-DCE6116C10A1Q37778184-85B6A8D3-82F1-4FF4-A73E-C22477B7F20AQ37799461-10BB5C2A-D172-4745-87EF-E997CBF5D31BQ37800008-A4F06E1D-CBFF-4D39-AE6F-94FEF1F09F38Q37829765-25B006A2-C5CA-4899-BEDD-BA324242E9BDQ37976876-E9FB7D46-E68B-4A75-B8C9-0867F4CC1F2CQ38016332-AD3D19EE-ECA9-4787-A11D-7596560E9202Q38028538-8674AE90-8DE8-4FED-BB05-5A681695004CQ38188035-B6F06008-145B-4870-B2B2-ED0CEB5194B2Q38672541-8AC79C83-0F0D-4948-8440-E4850598B7DBQ38675644-74A2A541-0FBD-443E-A93F-05629C06903CQ38736948-C550F580-3B38-46A2-B630-15C25CE4F424Q38771635-E5B78978-9049-4D6A-AE3B-C90EA4B6DEFDQ39189602-1C0C9333-3FEC-460C-A35C-C9FEBBB5A7B1Q39639394-EB8AF050-C9D4-43C0-8585-F424E70A58BAQ39959170-A9C0E873-230E-4DE7-BA95-150B8AC2CE9AQ40066314-A3B5FEE4-B113-4C7B-88A4-0FF412C903B9Q40420576-C7D80AEF-0698-43FE-903E-6460A9B8CC2A
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Simulation of clinical trials.
@ast
Simulation of clinical trials.
@en
type
label
Simulation of clinical trials.
@ast
Simulation of clinical trials.
@en
prefLabel
Simulation of clinical trials.
@ast
Simulation of clinical trials.
@en
P2093
P1476
Simulation of clinical trials.
@en
P2093
P304
P356
10.1146/ANNUREV.PHARMTOX.40.1.209
P577
2000-01-01T00:00:00Z